Photo by campaign_creators from unsplash
As part of the Centers for InterventionDevelopment and Applied Research (CIDAR) initiative funded by the National Institute of Mental Health, galantamine and oxytocin were included in a three-arm, six week… Click to show full abstract
As part of the Centers for InterventionDevelopment and Applied Research (CIDAR) initiative funded by the National Institute of Mental Health, galantamine and oxytocin were included in a three-arm, six week randomly controlled trial (ClinicalTrials.gov NCT01012167). Both medications are associated with mild side effect profiles (Hansen et al., 2008; Oya et al., 2016), are relatively inexpensive, and have shown efficacy in at least some studies (Lee et al., 2013). Unfortunately, data from the CIDAR trial failed to find significant improvements in negative symptom severity or cognitive functioning with either galantamine or oxytocin compared to placebo using standard clinical rating scales or neuropsychological test batteries (Buchanan et al., 2016). The present study reanalyzed these data using computerized measures of
Journal Title: Schizophrenia Research
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!